Anacor Pharmaceuticals (NASDAQ: ANAC) today announced that the arbitrator
appointed to resolve its dispute with Valeant Pharmaceuticals, Inc.
(NYSE: VRX), successor in interest to Dow Pharmaceutical Sciences, Inc.
(DPS), has issued an Interim Final Award in favor of Anacor, awarding
Anacor $ 100 million in damages as well as all costs of the arbitration
and reasonable attorney’s fees.
The parties may apprise the arbitrator of any issues not resolved in the
Interim Final Award order within ten days, and responses to any such
submission are due within fifteen days of the date of the Interim Final
Award. If no submissions are made, this Interim Final Award will become
See full press release